SCHEMBL12781069

SCHEMBL12781069

CNS(=O)(=O)c1cccc(Nc2nc(N)n(-c3nc4ccccc4s3)n2)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 3/20 0.49
▸ AXL P30530 1/20 0.45
▸ TNNI3K Q59H18 11/20 0.44
▸ EGFR P00533 2/20 0.44
▸ MEN1 O00255 1/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KIT P10721 1/20 0.41
▸ FLT3 P36888 1/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ TYK2 P29597 1/20 0.40
▸ JAK3 P52333 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12781074 0.89 BACE1 (0.55) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12780945 0.89 JAK3 (0.51) BACE1AXLEGFRMEN1MAPK1
SCHEMBL12781039 0.87 BACE1 (0.46) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12781080 0.86 SRC (0.49) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12781077 0.84 BACE1 (0.53) BACE1AXLMAPK1KMT2AMAPT
SCHEMBL12781007 0.83 BACE1 (0.46) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12780930 0.83 BACE1 (0.54) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12781000 0.82 BACE1 (0.56) BACE1AXLMEN1MAPK1KMT2A
SCHEMBL12781073 0.82 BACE1 (0.59) BACE1AXLMEN1KMT2AMAPT
SCHEMBL12781049 0.82 LMNA (0.55) BACE1MEN1MAPK1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885AXL 762/4885TNNI3K 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback